Approach to the thyroid cancer patient with bone metastases

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2296-2307

  Wexler, Jason A ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; ZOLEDRONIC ACID;

ADULT; BONE BIOPSY; BONE METASTASIS; CASE REPORT; CLIVUS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GAMMA KNIFE RADIOSURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SPINE METASTASIS; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; ADULT; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; RADIOSURGERY; RADIOTHERAPY; THYROID NEOPLASMS;

EID: 79961243923     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-1996     Document Type: Review

References (78)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
2. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18:784-791
3. Chen AY, Jemal A, Ward EM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807
4. Giusti F, Falchetti A, Franceschelli F, Marini F, Tanini A, Brandi ML 2010 Thyroid cancer: current molecular perspectives. J Oncol 2010:351679
5. McLeod DS 2010 Current concepts and future directions in differentiated thyroid cancer. Clin Biochem Rev 31:9-19
6. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
7. Sturgeon C, Angelos P 2006 Identification and treatment of aggressive thyroid cancers. Part 1: subtypes. Oncology (Williston Park) 20:253-260 (Pubitemid 46940204)
8. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803 (Pubitemid 43997716)
9. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899 (Pubitemid 44271732)
10. Fanchiang JK, Lin JD, Huang MJ, Shih HN 1998 Papillary and follicular thyroid carcinomas with bone metastases: a series of 39 cases during a period of 18 years. Changgeng Yi Xue Za Zhi 21:377-382
11. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598-605 (Pubitemid 126618447)
12. Roodman GD 2004 Mechanisms of bone metastasis. N Engl J Med 350:1655-1664
13. Selvaggi G, Scagliotti GV 2005 Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol 56:365-378 (Pubitemid 41677618)
14. Coleman RE 2006 Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s (Pubitemid 44703797)
15. Chua S, Gnanasegaran G, Cook GJ 2009 Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin Nucl Med 39:416-430
16. Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, Abe S, Nakano S, Nishino M, Ishigaki T, Naganawa S 2007 Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 48:889-895 (Pubitemid 46909916)
17. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A 2007 Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939-949 (Pubitemid 46766875)
18. Brage ME, Simon MA 1992 Evaluation, prognosis, and medical treatment considerations of metastatic bone tumors. Orthopedics 15:589-596
19. Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, Nakamoto Y, Higashi T, Saga T, Konishi J 2004 Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic -Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 31:491-498
20. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505 (Pubitemid 43236915)
21. Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, Wolffenbuttel BH, Dierckx RA, Links TP 2008 The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:958-965
22. Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Görges R, Müller SP, Bockisch A, Debatin JF, Brandau W 2004 Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14:2092-2098 (Pubitemid 39481183)
23. Rougraff BT 2003 Evaluation of the patient with carcinoma of unknown origin metastatic to bone. Clin Orthop Relat Res 415 Suppl:S105-S109 (Pubitemid 37323326)
24. Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, Elisei R, Pinchera A 1992 Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 74:1401-1404
25. Cignarelli M, Ambrosi A, Marino A, Lamacchia O, Campo M, Picca G, Giorgino F 2003 Diagnostic utility of thyroglobulin detection in fine-needle aspiration of cervical cystic metastatic lymph nodes from papillary thyroid cancer with negative cytology. Thyroid 13:1163-1167 (Pubitemid 38032402)
26. Cunha N, Rodrigues F, Curado F, Ilhéu O, Cruz C, Naidenov P, Rasca&tild;o MJ, Ganho J, Gomes I, Pereira H, Real O, Figueiredo P, Campos B, Valido F 2007 Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur J Endocrinol 157:101-107 (Pubitemid 47162572)
27. Schlumberger M, Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 19:1393-1400
28. Hoie J, Stenwig AE, Kullmann G, Lindegaard M 1988 Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer 61:1-6 (Pubitemid 18023102)
29. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA 1988 Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501-508
30. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306 (Pubitemid 28065257)
31. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G 2001 Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568-1573 (Pubitemid 32374905)
32. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL 1984 Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 57:323-327 (Pubitemid 14165273)
33. Marcocci C, Pacini F, Elisei R, Schipani E, Ceccarelli C, Miccoli P, Arganini M, Pinchera A 1989 Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 106:960-966 (Pubitemid 20012367)
34. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ 2000 Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10:261-268 (Pubitemid 30202413)
35. Proye CA, Dromer DH, Carnaille BM, Gontier AJ, Goropoulos A, Carpentier P, Lefebvre J, Decoulx M, Wemeau JL, Fossati P 1992 Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 16:640-645; discussion 645-646
36. Wood Jr WJ, Singletary SE, Hickey RC 1989 Current results of treatment for distant metastatic well-differentiated thyroid carcinoma. Arch Surg 124:1374-1377 (Pubitemid 20019065)
37. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960-967 (Pubitemid 16004302)
38. Lin JD, Huang MJ, Juang JH, Chao TC, Huang BY, Chen KW, Chen JY, Li KL, Chen JF, Ho YS 1999 Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 9:1227-1235
39. Petrich T, Widjaja A, Musholt TJ, Hofmann M, Brunkhorst T, Ehrenheim C, Oetting G, Knapp WH 2001 Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 28:203-208
40. Khorjekar G, Van Nostrand D, Moreau S, Atkins F, Mete M, Burman K, Wartofsky L 2010 Survival rate in patients diagnosed with well-differentiated thyroid cancer with bone metastases. J Nucl Med 51(Suppl 2):1591
41. Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R, Botta F, Maccauro M, Aliberti G, Seregni E, Lassmann M, Bombardieri E 2009 Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging 53:546-561
42. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL 1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937-941 (Pubitemid 13008961)
43. Maxon HR, Thomas SR, Samaratunga RC 1997 Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 7:183-187 (Pubitemid 27190577)
44. Sisson JC, Dewaraja YK, Wizauer EJ, Giordano TJ, Avram AM Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine. Thyroid 19:297-303
45. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K, Greenspan SL 1998 Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 83:2324-2330 (Pubitemid 28503022)
46. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G 2001 Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84:1586-1590 (Pubitemid 32612487)
47. Polascik TJ 2009 Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther 3:27-40
48. Pavlakis N, Schmidt R, Stockler M 2005 Bisphosphonates for breast cancer. Cochrane Database Syst Rev:CD003474
49. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD 2006 Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev:CD006250
50. Perazella MA, Markowitz GS 2008 Bisphosphonate nephrotoxicity. Kidney Int 74:1385-1393
51. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA 2011 The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53-58
52. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331
53. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491 (Pubitemid 351229318)
54. Woo SB, Hellstein JW, Kalmar JR 2006 Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761 (Pubitemid 46780635)
55. Visekruna M, Wilson D, McKiernan FE 2008 Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948-2952
56. Abrahamsen B, Eiken P, Eastell R 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095-1102
57. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research 2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
58. Lam MG, de Klerk JM, van Rijk PP, Zonnenberg BA 2007 Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem 7:381-397 (Pubitemid 47099046)
59. Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M 2006 Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35-41 (Pubitemid 43842022)
60. Greenblatt DY, Chen H 2007 Palliation of advanced thyroid malignancies. Surg Oncol 16:237-247 (Pubitemid 350192233)
61. Kushchayev S, Kushchayeva Y, Theodore N, Preul MC, Clark OH 2010 Percutaneous vertebroplasty for thyroid cancer metastases to the spine. Thyroid 20:555-560
62. Frassica DA 2003 General principles of external beam radiation therapy for skeletal metastases. Clin Orthop Relat Res 415 Suppl:S158-S164 (Pubitemid 37323333)
63. Brown RL 2008 Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol 35:298-308 (Pubitemid 351790737)
64. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB 2010 Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 15:146-156
65. Sandri A, Carbognin G, Regis D, Gaspari D, Calciolari C, Girardi V, Mansueto G, Bartolozzi P 2010 Combined radiofrequency and kyphoplasty in painful osteolytic metastases to vertebral bodies. Radiol Med 115:261-271
66. Brierley JD, Tsang RW 2008 External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 37:497-509, xi
67. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS 2009 Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74:1083-1091
68. Toyota N, Naito A, Kakizawa H, Hieda M, Hirai N, Tachikake T, Kimura T, Fukuda H, Ito K 2005 Radiofrequency ablation therapy combined with cementoplasty for painful bone metastases: initial experience. Cardiovasc Intervent Radiol 28:578-583 (Pubitemid 41367564)
69. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE 2006 Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 244:296-304 (Pubitemid 44305546)
70. Hoffmann RT, Jakobs TF, Trumm C, Weber C, Helmberger TK, Reiser MF 2008 Radiofrequency ablation in combination with osteoplasty in the treatment of painful metastatic bone disease. J Vasc Interv Radiol 19:419-425 (Pubitemid 351284538)
71. Robinson D, Yassin M, Nevo Z 2004 Cryotherapy of musculoskeletal tumors - from basic science to clinical results. Technol Cancer Res Treat 3:371-375 (Pubitemid 39096609)
72. Van Tol KM, Hew JM, Jager PL, Vermey A, Dullaart RP, Links TP 2000 Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 52:653-659 (Pubitemid 30337093)
73. Eustatia-Rutten CF, Romijn JA, Guijt MJ, Vielvoye GJ, van den Berg R, Corssmit EP, Pereira AM, Smit JW 2003 Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3184-3189 (Pubitemid 36877492)
74. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S 2009 Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564-1571
75. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A 2010 Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-5139
76. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
77. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
78. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42 (Pubitemid 351931094)